AR121292A1 - Vacuna contra hpv - Google Patents
Vacuna contra hpvInfo
- Publication number
- AR121292A1 AR121292A1 ARP210100329A ARP210100329A AR121292A1 AR 121292 A1 AR121292 A1 AR 121292A1 AR P210100329 A ARP210100329 A AR P210100329A AR P210100329 A ARP210100329 A AR P210100329A AR 121292 A1 AR121292 A1 AR 121292A1
- Authority
- AR
- Argentina
- Prior art keywords
- hpv
- vaccine against
- against hpv
- human papillomavirus
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación proporciona, entre otras cosas, una composición farmacéutica que incluye un adyuvante de nanopartículas lipídicas y una vacuna contra el virus del papiloma humano (HPV) que comprende partículas similares a virus (VLP) de HPV de al menos un tipo de virus del papiloma humano (HPV) seleccionado del grupo que consiste en los tipos de HPV: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062976673P | 2020-02-14 | 2020-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121292A1 true AR121292A1 (es) | 2022-05-04 |
Family
ID=74853762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100329A AR121292A1 (es) | 2020-02-14 | 2021-02-09 | Vacuna contra hpv |
Country Status (20)
Country | Link |
---|---|
US (3) | US11638754B2 (es) |
EP (1) | EP4103227A1 (es) |
JP (1) | JP2023516904A (es) |
KR (1) | KR20220140901A (es) |
CN (1) | CN115103687A (es) |
AR (1) | AR121292A1 (es) |
AU (1) | AU2021219652A1 (es) |
BR (1) | BR112022015313A2 (es) |
CA (1) | CA3166256A1 (es) |
CL (1) | CL2022002167A1 (es) |
CO (1) | CO2022011392A2 (es) |
CR (1) | CR20220395A (es) |
DO (1) | DOP2022000168A (es) |
EC (1) | ECSP22063122A (es) |
IL (1) | IL295234A (es) |
JO (1) | JOP20220187A1 (es) |
MX (1) | MX2022009964A (es) |
PE (1) | PE20230493A1 (es) |
TW (1) | TW202140069A (es) |
WO (1) | WO2021163002A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023023152A1 (en) * | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Thermostable lipid nanoparticle and methods of use thereof |
CN115850686A (zh) * | 2021-09-27 | 2023-03-28 | 广州谷森制药有限公司 | 新型氘代peg脂质化合物、其制备方法、组合物和应用 |
US11951177B2 (en) * | 2022-03-23 | 2024-04-09 | Nanovation Therapeutics Inc. | High sterol-containing lipid nanoparticles |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
ATE325875T1 (de) | 1994-10-07 | 2006-06-15 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
US5820870A (en) | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
EP0910343A1 (en) | 1996-07-03 | 1999-04-28 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
US7410795B2 (en) | 2002-12-23 | 2008-08-12 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
ES2381964T3 (es) | 2003-03-24 | 2012-06-04 | Merck Sharp & Dohme Corp. | Expresión optimizada de L1 de VPH 31 en levadura |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
KR101203403B1 (ko) | 2004-03-24 | 2012-11-21 | 머크 샤프 앤드 돔 코포레이션 | 효모에서 hpv 52 l1의 최적화된 발현 |
AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
AU2006336384B2 (en) | 2005-02-14 | 2010-12-16 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
KR20080005585A (ko) | 2005-04-26 | 2008-01-14 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
US7709010B2 (en) * | 2007-03-09 | 2010-05-04 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
US20100055168A1 (en) | 2008-04-16 | 2010-03-04 | Abbott Laboratories | Cationic lipids and uses thereof |
US20100076055A1 (en) | 2008-04-16 | 2010-03-25 | Abbott Laboratories | Cationic Lipids and Uses Thereof |
US20090285881A1 (en) | 2008-04-16 | 2009-11-19 | Abbott Laboratories | Cationic lipids and uses thereof |
US20100055169A1 (en) | 2008-04-16 | 2010-03-04 | Abbott Laboratories | Cationic lipids and uses thereof |
US20100104629A1 (en) | 2008-04-16 | 2010-04-29 | Abbott Laboratories | Cationic lipids and uses thereof |
US20090263407A1 (en) | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic Lipids and Uses Thereof |
WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
EP2326331A4 (en) | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION |
US20100099738A1 (en) | 2008-09-10 | 2010-04-22 | Abbott Laboratories | Polyethylene glycol lipid conjugates and uses thereof |
WO2010030739A1 (en) | 2008-09-10 | 2010-03-18 | Abbott Laboratories | Polyethylene glycol lipid conjugates and uses thereof |
AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
CA2754043A1 (en) | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
JPWO2010146740A1 (ja) | 2009-06-17 | 2012-11-29 | シャープ株式会社 | 表示駆動回路、表示装置及び表示駆動方法 |
EP2467357B1 (en) | 2009-08-20 | 2016-03-30 | Sirna Therapeutics, Inc. | Novel cationic lipids with various head groups for oligonucleotide delivery |
SG10201407996PA (en) | 2009-12-23 | 2015-01-29 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
ES2384060B1 (es) | 2010-03-24 | 2013-09-23 | Lipotec S.A. | Cápsulas de nanopartículas lipídicas. |
EP3144015B1 (en) | 2010-09-20 | 2021-06-02 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
ES2762230T3 (es) | 2011-06-24 | 2020-05-22 | Merck Sharp & Dohme | Formulaciones de vacuna contra el HPV que comprenden un adyuvante de aluminio y métodos de producción de las mismas |
EP3110401A4 (en) | 2014-02-25 | 2017-10-25 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
EP3364982A4 (en) * | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
-
2021
- 2021-02-09 IL IL295234A patent/IL295234A/en unknown
- 2021-02-09 CN CN202180014380.2A patent/CN115103687A/zh active Pending
- 2021-02-09 CA CA3166256A patent/CA3166256A1/en active Pending
- 2021-02-09 JO JOP/2022/0187A patent/JOP20220187A1/ar unknown
- 2021-02-09 PE PE2022001736A patent/PE20230493A1/es unknown
- 2021-02-09 EP EP21709566.0A patent/EP4103227A1/en active Pending
- 2021-02-09 AU AU2021219652A patent/AU2021219652A1/en active Pending
- 2021-02-09 JP JP2022548590A patent/JP2023516904A/ja active Pending
- 2021-02-09 MX MX2022009964A patent/MX2022009964A/es unknown
- 2021-02-09 WO PCT/US2021/017157 patent/WO2021163002A1/en active Application Filing
- 2021-02-09 AR ARP210100329A patent/AR121292A1/es unknown
- 2021-02-09 TW TW110104887A patent/TW202140069A/zh unknown
- 2021-02-09 US US17/170,948 patent/US11638754B2/en active Active
- 2021-02-09 BR BR112022015313A patent/BR112022015313A2/pt unknown
- 2021-02-09 CR CR20220395A patent/CR20220395A/es unknown
- 2021-02-09 KR KR1020227031070A patent/KR20220140901A/ko unknown
- 2021-02-09 US US17/799,464 patent/US20230123584A1/en active Pending
-
2022
- 2022-08-10 CL CL2022002167A patent/CL2022002167A1/es unknown
- 2022-08-11 EC ECSENADI202263122A patent/ECSP22063122A/es unknown
- 2022-08-12 DO DO2022000168A patent/DOP2022000168A/es unknown
- 2022-08-12 CO CONC2022/0011392A patent/CO2022011392A2/es unknown
-
2023
- 2023-03-10 US US18/181,754 patent/US20230270850A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022009964A (es) | 2022-09-19 |
EP4103227A1 (en) | 2022-12-21 |
US11638754B2 (en) | 2023-05-02 |
JP2023516904A (ja) | 2023-04-21 |
CR20220395A (es) | 2022-10-27 |
IL295234A (en) | 2022-10-01 |
JOP20220187A1 (ar) | 2023-01-30 |
US20210252138A1 (en) | 2021-08-19 |
US20230270850A1 (en) | 2023-08-31 |
WO2021163002A1 (en) | 2021-08-19 |
CN115103687A (zh) | 2022-09-23 |
TW202140069A (zh) | 2021-11-01 |
AU2021219652A1 (en) | 2022-08-18 |
CO2022011392A2 (es) | 2022-08-19 |
CA3166256A1 (en) | 2021-08-19 |
ECSP22063122A (es) | 2022-11-30 |
DOP2022000168A (es) | 2022-09-30 |
KR20220140901A (ko) | 2022-10-18 |
BR112022015313A2 (pt) | 2022-09-27 |
CL2022002167A1 (es) | 2023-02-03 |
PE20230493A1 (es) | 2023-03-23 |
US20230123584A1 (en) | 2023-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022011392A2 (es) | Vacuna contra hpv | |
AR055603A1 (es) | Vacuna contra la infeccion por virus del dengue | |
AR064009A1 (es) | Metodo de inmunizacion contra los 4 serotipos del dengue | |
CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
AR106026A1 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
PE20150356A1 (es) | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue | |
CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
BR112013030150A2 (pt) | proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma | |
CU20180025A7 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
MX2021002586A (es) | Dosis unitaria de vacuna contra el dengue y administracion de esta. | |
AR103427A1 (es) | Vacuna contra la fiebre aftosa | |
PH12018500458A1 (en) | Vlp stabilized vaccine compositions | |
AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
CO6341567A2 (es) | Vacuna contra el virus de papiloma humano | |
CO2022017989A2 (es) | Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas | |
BR112016025977A2 (pt) | composições, métodos e utilizações para formulações de papilomavirus humano estábulo estável | |
MX2019012620A (es) | Composiciones de vacunas. | |
CL2013002723A1 (es) | Metodo de produccion de una particula semejante a virus (vlp) de alfavirus salmonido (sav) en celulas de insecto. | |
CL2020002876A1 (es) | Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420) | |
UY38933A (es) | Vacuna de partículas tipo virus del chicunguña y métodos para su uso | |
AR097881A1 (es) | FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO | |
AR126708A1 (es) | Vacuna para el vph | |
AR120296A1 (es) | Vacuna de partículas de virus de tipo chikungunya y sus métodos de uso | |
AR074485A1 (es) | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |